Inching toward a serogroup B meningococcal vaccine for infants

JAMA

Volumn 307, Issue 6, 2012, Pages 614-615

  Cohn, Amanda C ^a   Messonnier, Nancy E ^a  

^a NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL ANTIGEN; FACTOR H BINDING PROTEIN; MENINGOCOCCUS VACCINE; NEISSERIA HEPARIN BINDING ANTIGEN; NEISSERIAL ADHESIN A; OUTER MEMBRANE VESICLE ANTIGEN; PERTACTIN; PERTUSSIS VACCINE; PNEUMOCOCCUS VACCINE; UNCLASSIFIED DRUG;

ANTIBODY TITER; ANTIGEN EXPRESSION; BACTERIAL GENOME; BACTERIAL STRAIN; DOSAGE SCHEDULE COMPARISON; DRUG FEVER; DRUG SAFETY; EDITORIAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEBRILE CONVULSION; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFANT; MENINGOCOCCOSIS; NEISSERIA MENINGITIDIS; PRIORITY JOURNAL; VACCINATION;

EID: 84856801065     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2012.118     Document Type: Editorial

References (14)

1. Trotter CL, Andrews NJ, Kaczmarski EB, Miller E, Ramsay ME. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet. 2004;364(9431):365-367. (Pubitemid 38970013)
2. Macneil JR, Cohn AC, Zell ER, et al; Active Bacterial Core surveillance (ABCs) Team and MeningNet Surveillance Partners. Early estimate of the effectiveness of quadrivalent meningococcal conjugate vaccine. Pediatr Infect Dis J. 2011;30 (6):451-455.
3. Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine. 2009;27(suppl 2):B51-B63.
4. Cohn AC, MacNeil JR, Harrison LH, et al. Changes in Neisseria meningitidis disease epidemiology in the United States, 1998-2007: implications for prevention of meningococcal disease. Clin Infect Dis. 2010;50(2):184-191.
5. Meningococcal vaccines: WHO position paper, November 2011. Wkly Epidemiol Rec. 2011;86(47):521-539.
6. Gossger N, Snape MD, Yu L-M, et al; for the European MenB Vaccine Study Group. Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial. JAMA. 2012; 307(6):573-582.
7. Donnelly J, Medini D, Giuliani M, et al. Estimating the potential strain coverage in Europe of a multicomponent vaccine targeting serogroup B meningococci. Presented at: Meningitis Research Foundation Conference 2011; November 8-9, 2011; London, United Kingdom.
8. Auckland C, Gray S, Borrow R, et al. Clinical and immunologic risk factors for meningococcal C conjugate vaccine failure in the United Kingdom. J Infect Dis. 2006;194(12):1745-1752. (Pubitemid 44902007)
9. Wang X, Cohn A, Comanducci M, et al. Prevalence and genetic diversity of candidate vaccine antigens among invasive Neisseria meningitidis isolates in the United States. Vaccine. 2011;29(29-30):4739-4744.
10. Giuliani MM, Biolchi A, Serruto D, et al. Measuring antigen-specific bactericidal responses to amulticomponent vaccine against serogroup Bmeningococcus. Vaccine. 2010;28(31):5023-5030.
11. Borrow R, Dagan R, Zepp F, Hallander H, Poolman J. Glycoconjugate vaccines and immune interactions, and implications for vaccination schedules. Expert Rev Vaccines. 2011;10(11):1621-1631.
12. Nøkleby H, Aavitsland P, O'Hallahan J, Feiring B, Tilman S, Oster P. Safety review: two outer membrane vesicle (OMV) vaccines against systemic Neisseria meningitidis serogroup B disease. Vaccine. 2007;25(16):3080-3084. (Pubitemid 46505045)
13. Maiden MCJ, Stuart JM; UK Meningococcal Carraige Group. Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination. Lancet. 2002;359(9320):1829-1831.
14. Snape MD, Kelly DF, Salt P, et al. Serogroup C meningococcal glycoconjugate vaccine in adolescents: persistence of bactericidal antibodies and kinetics of the immune response to a booster vaccine more than 3 years after immunization. Clin Infect Dis. 2006;43(11):1387-1394. (Pubitemid 44845637)